Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.47 |
| ▸ | DUSP1 | P28562 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085606 | 0.81 | MEN1 (0.55) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6086892 | 0.81 | USP2 (0.74) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6084643 | 0.81 | KDM4E (0.60) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6084151 | 0.80 | MAPT (0.61) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6085534 | 0.80 | CETP (0.49) | POLBNPC1RAB9AMAPT | |
| SCHEMBL6085757 | 0.78 | NAMPT (0.55) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6084168 | 0.76 | MAPT (0.70) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6086289 | 0.76 | P2RY14 (0.62) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6084978 | 0.76 | P2RY14 (0.61) | HSD17B10KDM4ETSHRUSP2ALDH1A1 | |
| SCHEMBL6086913 | 0.76 | HSD17B10 (0.53) | HSD17B10KDM4ETSHRUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | HSD17B10 3948/4885KDM4E 1175/4885TSHR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.